Fosfomycin in a Traumatological Department

Casado, Verónica

doi:10.1159/000222082

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in this analysis) were treated with fosfomycin for osteomyelitis (acute or chronic, hematogenous, vertebral, post-traumatic, post-operative or in the presence of diabetic foot infectionlimb threatening osteomyelitis). Arthritis, pyogenic discitis, septic pseudoarthrosis, internal fixation infection and periprosthetic joint infections were some of the other indications for which intravenous fosfomycin was administered [5,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43].…”

Section: Article Highlightsmentioning

confidence: 99%

Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review

Tsegka

Voulgaris

Kyriakidou

et al. 2021

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Fosfomycin is a wide spectrum bactericidal antibiotic with a unique mode of action, low toxicity, and good penetration in tissues with deep-seated infections, including bone and joint infections. Areas covered: Data were extracted from 19 published articles. Three hundred and sixty-five patients, with broad age range, received intravenous fosfomycin for the treatment of bone and joint infections (including arthritis, acute and chronic osteomyelitis, discitis, periprosthetic joint infection). Fosfomycin was given as part of a combination antimicrobial therapy in the majority of patients (93.7%). The dosage of fosfomycin ranged from 4 g/day (in one case) to 24 g/day. The dosage of fosfomycin, in some cases, mostly pediatric, was calculated based on body weight, ranging from 50 mg/kg/day to 250 mg/kg/day. The duration of fosfomycin treatment ranged from a couple of days up to 3 months. The most common isolated pathogen was Staphylococcus aureus (38.9%). Three hundred patients (82.2%) were successfully treated. Fosfomycin was well tolerated, as few patients developed mild adverse events, mostly gastrointestinal discomfort, hypernatremia, skin rash, and neutropenia. Expert opinion: The available data suggests that intravenous fosfomycin may be beneficial for the treatment of patients with bone and joint infections, especially when used as part of a combination antibiotic regimen.

show abstract

Section: Article Highlightsmentioning

confidence: 99%

Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review

Tsegka

Voulgaris

Kyriakidou

et al. 2021

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…There is considerable clinical experience regarding the use of fosfomycin, mainly in combination regimens, for various types of bone infections [69], primarily complicated bone fractures [70] and osteomyelitis or septic arthritis in children [71,72]. It is noteworthy that a recent survey among paediatricians and paediatric orthopaedists in France found that the combination of fosfomycin with a third-generation cephalosporin was one of the most popular therapeutic options for acute osteomyelitis in children [73].…”

Section: Bone Infectionsmentioning

confidence: 99%

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

Roussos

Karageorgopoulos

Samonis

et al. 2009

International Journal of Antimicrobial Agents

162

151

View full text Add to dashboard Cite

show abstract

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database

et al. 2015

View full text Add to dashboard Cite

IntroductionThe growing problem of antibacterial resistance resulted in an increased interest in fosfomycin, especially its parenteral formulation. We reviewed fosfomycin safety profile using the Food and Drug Administration Adverse Event (AE) Reporting System (FAERS) and published literature.MethodsWe conducted a FAERS search and disproportionality analysis of all fosfomycin-associated AEs. We also conducted a FAERS search for AEs implicating fosfomycin as the primary suspect and a search of reports of fosfomycin-associated bone marrow toxicity. We then review the literature for publications reporting AEs associated with fosfomycin by conducting PubMed searches.ResultsThe disproportionality analysis of all FAERS reports of fosfomycin-associated AEs produced a higher than expected frequency of agranulocytosis, liver injury, severe skin reactions, and pseudomembranous colitis. Subsequent search for AEs where fosfomycin was the primary suspect and the literature review did not suggest a higher association of fosfomycin with these AEs. The search of bone marrow toxicity reports did not demonstrate an association between aplastic anemia and fosfomycin. The literature review selected 23 trials of parenteral administration of fosfomycin in 1242 patients including 8 comparative and 15 non-comparative trials. For oral fosfomycin, only prospective comparative trials (n = 28) in 2743 patients were included. The most frequent AEs associated with parenteral fosfomycin included rash, peripheral phlebitis, hypokalemia, and gastrointestinal disorders. Serious AEs such as aplastic anemia, anaphylaxis, and liver toxicities were reported infrequently. Gastrointestinal disorders were the most common AEs associated with oral fosfomycin.ConclusionThe identified AEs were consistent with the safety profile of fosfomycin. No new safety signals related to either parenteral or oral fosfomycin were identified.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-015-0092-8) contains supplementary material, which is available to authorized users.

show abstract

Fosfomycin in a Traumatological Department

Cited by 7 publications

References 0 publications

Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review

Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database

Contact Info

Product

Resources

About